FDA Approves Encorafenib Plus Cetuximab for Metastatic CRC with BRAF V600E Mutation

The FDA approved the combination use of encorafenib and cetuximab for the treatment of adult patients with  BRAFV600E-positive metastatic colorectal cancer.

Source: CancerNetwork - April 9, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news